Patents
Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210)
03/2009
03/26/2009US20090081652 Constitutively Translocating Cell Line
03/26/2009US20090081651 METHODS FOR ISOLATING AND CHARACTERIZING ENDOGENOUS mRNA-PROTEIN (mRNP) COMPLEXES
03/26/2009US20090081645 Method of assuming drug sensitivity to cdk4 inhibitor
03/26/2009US20090081642 Novel apoptosis gene EI24, compositions, and methods of use
03/26/2009US20090081637 Screening nucleic acid comprising sequence that encodes reverse transciptase domain of DNA polymerase for adefovir-resistant mutations; use in vaccine development
03/26/2009US20090081635 Modified heparinase iii and methods of sequencing therewith
03/26/2009US20090081354 Phytate Polynucleotides and Methods of Use
03/26/2009US20090081353 Corn plants and seed enhanced for asparagine and protein
03/26/2009US20090081331 Phytase
03/26/2009US20090081283 Tumor therapy with non-viral-based high affinitiy laminin receptor-targeted vectors
03/26/2009US20090081280 Compositions and methods for modulating hemostasis
03/26/2009US20090081263 Double-stranded rna oligonucleotides which inhibit tyrosinase expression
03/26/2009US20090081256 Transgenic plant-based vaccines
03/26/2009US20090081251 Production of Viral Vaccines in Suspension on Avian Embryonic Derived Stem Cell Lines
03/26/2009US20090081248 Non-hemolytic LLO fusion proteins and methods of utilizing same
03/26/2009US20090081243 Agents and methods for diagnosing stress
03/26/2009US20090081242 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
03/26/2009US20090081241 comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein
03/26/2009US20090081240 Human Anti-Kir Antibodies
03/26/2009US20090081239 bind and neutralize Plasminogen Activator Inhibitor-1 (PAI-1) by converting PAI-1 to its latent form or increasing proteolytic cleavage; treating a fibrotic condition; inhibits accumulation of extracellular matrix (ECM)
03/26/2009US20090081238 Anti-notch1 NRR antibodies and methods using same
03/26/2009US20090081230 Human cytomegalovirus neutralising antibodies and use thereof
03/26/2009US20090081229 Anti-pro87299 antibodies
03/26/2009US20090081228 Cyr61 compositions and methods
03/26/2009US20090081227 Promotong differentiation of neural stem cells to nerve cells for use in treating injury to central nerve system caused by brain infarction, hemorrhage and/or spinal cord injury
03/26/2009US20090081225 PIF peptides biologic activities, site of action, and the antibody to detect PIF
03/26/2009US20090081224 Compositions of polypeptides specific to pathogenic strains and their use as vaccines and in immunotheraphy
03/26/2009US20090081222 Novel splice variants of the egf receptor
03/26/2009US20090081215 Genetic products differentially expressed in tumors and use thereof
03/26/2009US20090081214 Genetic products differentially expressed in tumors and use thereof
03/26/2009US20090081210 Methods of Killing Tumor Cells by Targeting Internal Antigens Exposed on Apoptotic Tumor Cells
03/26/2009US20090081209 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins
03/26/2009US20090081207 High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity
03/26/2009US20090081202 Immunogenic compositions and methods
03/26/2009US20090081193 Hemagglutinin polypeptides, and reagents and methods relating thereto
03/26/2009US20090081185 Apoptotic agents
03/26/2009US20090081178 Phenolic Binding Peptides
03/26/2009US20090081172 Nucleic acid encoding a receptor other than an immunoglobulin, wherein the receptor binds to a MUC 1 tumor antigen independently of a major histocompatibility complex (MHC); activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor
03/26/2009US20090081166 Colonization factor (CF) antigens of enterotoxigenic escherichia coli in recombinant bacteria
03/26/2009US20090081144 Cosmetic compositions
03/26/2009US20090081131 Tumor therapy with high affinity laminin receptor-targeted vectors and compounds
03/26/2009US20090081127 Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
03/26/2009US20090081126 Novel fully human anti-VAP-1 monoclonal antibodies
03/26/2009US20090081125 Angiogenetic Agent Containing Adrenomedulin as the Active Ingredient
03/26/2009US20090081124 Virus coat protein/receptor chimeras and methods of use
03/26/2009US20090081119 Inhibiting dna polymerase beta to enhance efficacy of anticancer agents
03/26/2009US20090078645 Plant Capable of Accumulating Inorganic Phosphate at High Level and Use of the Plant
03/26/2009US20090078574 Charge tags and the separation of nucleic acid molecules
03/26/2009US20090078384 Esterases from rumen
03/26/2009CA2712326A1 Plants with increased yield
03/26/2009CA2711818A1 Method of reducing the effects of cytostatic drugs on bone marrow derived cells, and methods of screening
03/26/2009CA2706889A1 Mutant pyrrolysyl-trna synthetase, and method for production of protein having non-natural amino acid integrated therein by using the same
03/26/2009CA2701871A1 Plants with increased yield
03/26/2009CA2700476A1 Methods and compositions for detection of ehrlichia chaffeensis (vlpt)
03/26/2009CA2700474A1 Methods and compositions for detection of ehrlichia chaffeensis (p120)
03/26/2009CA2700294A1 Plants having increased yield-related traits and a method for making the same
03/26/2009CA2700265A1 Compositions and methods for altering the morphology of plants
03/26/2009CA2700115A1 Long interspersed nuclear element polypeptide compositions and methods of use thereof
03/26/2009CA2700047A1 Hypoallergenic variants of the major allergen from betula verrucosa pollen
03/26/2009CA2699998A1 Compositions comprising stat5 sirna and methods of use thereof
03/26/2009CA2699995A1 Compositions comprising stat3 sirna and methods of use thereof
03/26/2009CA2699958A1 Identification and isolation of fetal cells and nucleic acid
03/26/2009CA2699944A1 Targeted interferon demonstrates potent apoptotic and anti-tumor activities
03/26/2009CA2699638A1 Down-regulation of the gene expression by means of nucleic acid-loaded virus-like particles
03/26/2009CA2698908A1 Methods of refining hydrocarbon feedstocks
03/26/2009CA2698667A1 Human gm-csf antigen binding proteins
03/26/2009CA2698460A1 Compositions and methods for the modification of physiological responses in plants
03/26/2009CA2698130A1 Modified xylan production
03/26/2009CA2694494A1 Hpiv-2 variants and medical applications thereof
03/25/2009EP2040187A1 Gene information processing apparatus and gene information display apparatus
03/25/2009EP2039782A2 Method and apparatus for judging the presence or absence of cancer cell
03/25/2009EP2039779A1 Screening method
03/25/2009EP2039774A1 Methods for the production of products in host cells
03/25/2009EP2039773A1 Mutant vesicular stomatitis viruses and use thereof
03/25/2009EP2039772A2 Method for improved utilization of the production potential of transgenic plants introduction
03/25/2009EP2039771A2 Method for improved utilization of the production potential of transgenic plants
03/25/2009EP2039770A2 Method for improved utilization of the production potential of transgenic plants
03/25/2009EP2039769A2 Antimicrobial peptides and methods of use
03/25/2009EP2039768A1 Mutant forms of Fas ligand and uses thereof
03/25/2009EP2039767A1 PNA conjugates targeted to the EMU enhancer of the IGH locus as therapeutic agent for BCL-2 translocation-driven follicular cell lymphoma clonal expansion
03/25/2009EP2039766A1 Immunocompetent cell having anti-cd38 antibody on its cell surface
03/25/2009EP2039765A1 Method for determination of 1,5-anhydroglucitol, and reagent composition for determination of 1,5-anhydroglucitol
03/25/2009EP2039764A1 Truncated secretory aspartyl proteinase 2
03/25/2009EP2039762A2 Nitralases
03/25/2009EP2039704A1 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
03/25/2009EP2039367A1 Prophylactic/therapeutic agent for neurodegenerative disease
03/25/2009EP2039251A1 Methods for generating genetically altered antibody-producing cell lines with improved antibody characteristics
03/25/2009EP2039239A1 Method for preventing mutation of pathogens exposed to transgenic plants
03/25/2009EP2038421A2 A molecular tool to enhance salt tolerance in an organism
03/25/2009EP2038420A2 Use of multiple transformation enhancer sequences to improve plant transformation efficiency
03/25/2009EP2038419A1 Transplastomic plants expressing lumen-targeted protein
03/25/2009EP2038418A2 Dna molecules and methods
03/25/2009EP2038417A2 Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
03/25/2009EP2038416A1 Nitrogen limitation adaptibility gene and protein and modulation thereof
03/25/2009EP2038415A1 Dph2 gene deletion mutant and uses thereof
03/25/2009EP2038414A2 Cancer therapy using bcl-xl-specific sina
03/25/2009EP2038413A2 Apparatus, compositions, and methods for assessment of chronic obstructive pulmonary disease progression among rapid and slow decline conditions
03/25/2009EP2038412A1 Polynucleotides encoding caryophyllene synthase and uses thereof
03/25/2009EP2038409A2 Novel human acidic mammalian chitinase and use thereof
03/25/2009EP2038408A1 Preparation of dough and baked products